AOP Orphan Pharmaceuticals AG
18
2
3
14
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 18 trials
100.0%
+13.5% vs industry average
56%
10 trials in Phase 3/4
0%
0 of 14 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (18)
Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH
Role: lead
A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients
Role: lead
The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV
Role: collaborator
A Prospective Non-interventional Observational Study to Observe Long-term Treatment and Outcomes in Pulmonary Arterial Hypertension (PAH) Patients
Role: lead
Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
Role: lead
ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission
Role: collaborator
AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.
Role: lead
Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response
Role: collaborator
Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera
Role: lead
Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera
Role: lead
Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia
Role: lead
Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients
Role: lead
Anagrelide Retard in Essential Thrombocythemia
Role: lead
Long-term PK and Safety/Tolerability Testing LDLL600 Against Esmolol in Healthy Volunteers
Role: lead
A Pharmacokinetic, Pharmacodynamic, Safety Study With AOP LDLA202, ONO LDL50 and Esmolol in Healthy Volunteers
Role: lead
A Short Term Pharmacokinetic, Pharmacodynamic and Tolerability Study to Compare AOP200704 vs. Esmolol
Role: lead
Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia
Role: lead
Lancovutide (Moli1901) Inhalation Solution Study in Adolescents and Adults With Cystic Fibrosis
Role: lead
All 18 trials loaded